LAS VEGAS, Oct. 19, 2016 /PRNewswire/ -- Interpace
Diagnostics Group (NASDAQ: IDXG), a company that provides
specialized molecular diagnostic tests and pathology services,
reported today, from the American College of Gastroenterology (ACG)
Annual Meeting in Las Vegas, NV,
the publication of a study supporting the company's newly launched
PanDNA® product. The study, led and presented by Dr.
James Farrell, Director of the Yale
Center for Pancreatic Diseases, describes when and how PanDNA can
help assess long term risk of pancreatic cancer in patients with
pancreatic cystic lesions. The presentation took place during
the Pancreatico-Biliary / Endoscopy Plenary Session. Over 5,000
Gastroenterologists attend the ACG Annual Meeting and participate
in various courses related to a wide variety of gastrointestinal
disease, including Pancreatic Cancer.
PanDNA examines the accumulation of three key molecular
abnormalities that have been associated with cancer in pancreatic
cysts: elevated DNA quantity; Oncogene mutations; and Tumor
Suppressor Gene Mutations. Dr. Farrell and his coauthors
extend these past findings to show how such molecular information
can be used to help physicians assess a patient's long term risk of
cancer. Depending on the individual characteristics of a
patient's cyst, the study reports that accumulation of these key
molecular abnormalities can be an indication that a patient is at
high risk of cancer. Importantly, the study also shows that the
absence of all molecular abnormalities can be an indication that a
patient is at low, long term risk of cancer. Long term risk
of cancer was evaluated in patients followed for up to 8 years
after molecular testing.
Over 170,000 patients in the US annually are identified with
pancreatic cysts via imaging studies and referred by Radiologists
to a Gastroenterologist for further risk assessment resulting in
critical decisions for observation of patients or decisions to
surgically remove the lesion. PanDNA can provide physicians
making those decisions with additional information about a
patient's long term potential for developing cancer. The key
molecular components of PanDNA have been evaluated in over 27,000
patients. This data will provide further support of the Company's
ongoing launch of the PanDNA product to those clinicians that find
value in the specific molecular data provided for each patient.
"We're excited to see strong, long term follow-up evidence
supporting the ability of PanDNA to provide clinicians with
additional information to better assess a patient's risk of cancer
presented by a thought leader of Dr. Farrell's caliber" said
Jack Stover, President and CEO of
Interpace. "Having this data presented at a prestigious conference
like the ACG demonstrates Interpace's continued commitment and
contribution to improving patient care."
About PanDNA®
PanDNA® is a pancreatic cyst molecular test that, by using a small
sample of pancreatic cyst fluid, can aid in pancreatic cancer risk
assessment. Pancreatic cancer is often difficult to diagnose in
early stages and typically spreads rapidly with signs and symptoms
appearing when the cancer is significantly advanced. Because of
this, and that complete surgical removal of the pancreas is not
possible, pancreatic cancer is considered a leading cause of cancer
deaths.
About PancraGEN®
PancraGEN® is a pancreatic cyst molecular test that, by using a
small sample of pancreatic cyst fluid, can aid in pancreatic cancer
risk assessment. PancraGEN® is 90% accurate, according to clinical
studies, enabling effective risk stratification of patients.
Pancreatic cancer is often difficult to diagnose in early stages
and typically spreads rapidly with signs and symptoms appearing
when the cancer is significantly advanced. Because of this, and
that complete surgical removal of the pancreas is not possible,
pancreatic cancer is considered a leading cause of cancer
deaths.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for better patient diagnosis and management. The Company currently
has three commercialized molecular tests: PancraGen® for
the evaluation of pancreatic cysts and assessment of risk of
concomitant or subsequent cancer; ThyGenX®, for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
next generation sequencing assay; and ThyraMIR®, for the
diagnosis of thyroid cancer from thyroid nodules utilizing a
proprietary gene expression assay. Interpace Diagnostics mission is
to provide personalized medicine through molecular diagnostics and
innovation to advance patient care based on rigorous science.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995, relating to our future financial and operating
performance. The company has attempted to identify forward looking
statements by terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "projects," "intends,"
"potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking
statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond company's control. These statements also involve known and
unknown risks, uncertainties and other factors that may cause
company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, our ability to adequately finance the business, our
ability to restructure our debt and other obligations, the market's
acceptance of our molecular diagnostic tests, our ability to secure
additional business and generate higher profit margins through
sales of our molecular diagnostic tests, in-licensing or other
means, projections of future revenues, growth, gross profit and
anticipated internal rate of return on investments. Additionally,
all forward-looking statements are subject to the risk factors
detailed from time to time in the company's periodic filings with
the Securities and Exchange Commission (SEC), including without
limitation, the Annual Report on Form 10-K filed with the SEC on
March 30, 2016, as amended on
April 29, 2016 and June 14, 2016. Because of these and other
risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these
statements speak only as of the date of this press release and,
except as may be required by law, the Company undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
CONTACT:
Investor Relations:
Victor Roberts
RedChip Companies, Inc.
(407)644-4256, ext. 111
victor@redchip.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/evidence-supporting-interpace-diagnostics-pandna--product-presented-at-the-american-college-of-gastroenterology-annual-meeting-300347749.html
SOURCE Interpace Diagnostics Group, Inc.